The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
So what do we have?
It seems blatantly obvious to me that people knew about the pending settlement- hence the rise to 16p. It’s the only reason and you can’t tell me otherwise. Once again the normal PI is screwed.
TW has been remarkably silent hasn’t he? Clown. He will just say his sound bite about insider trading was about something else.
Some large sales just before figures are due....yet again we are being screwed.
Unfortunately this is just a POS - Reynolds is a clown. REAT - POS. BIG SOFA - POS. NIPT - car crash.
Someone from NIPT that no longer works there once told me, amongst other things, that AR would be the hero of AIM.... he’s actually the joke. It would be funny if he wasn’t making a fortune and all us a screwed.
PI panic and something else - the trades have been too big... It's not forward selling just above 10 and under - that makes zero sense and wouldnt worth their while.
This could have been prevented by FN communication from the company. Utter FN shambles.
Is anyone going the AGM???
What is going on is a complete disregard for PIs - this could have easily been prevented by clear communication re the settlement, clarity re TF, positive spin re the future. But no , nothing, complete incommunicado from the company.
Barry how do you sleep at night??? Fn clowns the lot of them - not one of us would have invested in this company knowing what we know now re the product nor the actions of the BOD.
Yes because infringing on another companies patents, getting screwed out of nearly a million quid by genoma and seeing the SP go down to 3p and allowing finncapp to f up the most recent placing is brilliant management of the company isn't it? I applaud the BOD for dilution and being less than listing price.
Us LTHs are not happy because we are fully aware of the omnishambles this company has been thus far.
You are 100% correct.
Only these could cock it up so bad - I don't know how they sleep at night. Clowns.
It's an utter disgrace that the SP has fallen nigh on 40% from the settlement need we have waited for. The way they handled it is shambolic. Utterly shambolic.
I'd just like to thank Premaitha for accentuating the positive and getting some quality communications out after the illumina deal was sorted. Id like to thank them for striking whilst the iron was hot - because if they didn't there may have been a huge fall in the share price and us PIs that have been put through the grinder due to their patent infringement wouldn't have deserved that would we? So well done Premaitha.
A few of us have spoken to the company and TF green lighted this and we continue to work with TF in a long term partnership mode for NIPT AND future products.
England and the EU is not our focus now for NIPT and the percentage of our busibess that is in this area will continue to fall as it grows outside this area.
Thermo have lots of shares and vested interest in Premaitha and as flipper says WE are their route into it.
Will they take us over and ring fence the EU as a separate entity?
Or would illumina try to take us over to this benefit from our rapidly growing non EU business and try to migrate it over to their platforms?
Either way it's all good for us and THE black swan has gone.
Has any one listened to the bearcast today re Premaitha???
This is the news we have been waiting; for the elephant in the room is dead, the monkey is off the back, the skeleton in the cupboard is dust and the black swan is cooked.
We now have complete transparency going forward.
Just to clarify (as per Premaitha directly) - NOTHING changes with Thermo. We will still use them outside of the EU/Patent areas. The EU is now ring fenced with illumina but the lions share of our territory remains exactly the same -
using TF,
paying no royalty payments,
Growing impressively (wait for the figures)
I understand that TF gave the green light for this deal with illumina.
Once the traders settle and the figures are out it's full steam ahead.
Good luck to all the long term holders.
These blatant rampers from the last few days - do one, we are not stupid.
VV.
From the news section of abnova.
http://www.abnova.com/aboutus/news_detail.asp?CTID={FD47C71F-1EFF-42DB-A061-03D8E69C3876}
Neihu, Taiwan (June 26, 2018)
Abnova and Yourgene announced today to collaborate and accelerate next generation sequencing (NGS) capability for single cell analysis in Taiwan. Abnova has successfully developed a large portfolio of cell-based liquid biopsy technologies for enrichment and isolation of circulating tumor cell (CTC) and circulating fetal cell (CFC) technologies in recent years. Yourgene is one of the recognized world leaders of NGS analysis for both academic research and non-invasive prenatal testing/screening (NIPT, NIPS) and was successfully acquired by Premaitha Health, a public listed company in United Kingdom, last year. Both Abnova and Yourgene will work together to build the single cell NGS infrastructure for point mutation, insertion and deletion (INDEL), gene fusion, copy number variation (CNV), and chromosomal aneuploidies for the analysis of CTCs and CFCs. Both companies aim to efficiently integrate each other’s upstream and downstream capabilities to speed up single cell’s laboratory-developed test (LDT) and in vitro diagnostics (IVD) application and commercialization for the cancer and prenatal markets.
“Single cell analysis has gained increased importance in precision medicine, particularly for cancer and prenatal markets,” said Dr. Wilber Huang, President of Abnova Corporation. “On the cancer front, this is evidenced by tumor’s single cell heterogeneity which propels the physicians and patients to identify more tumor mutations, tumor burden, and RNA signature to improve drug guidance, particularly in the new era of immunotherapy. On the prenatal front, the renewed enthusiasm for fetal cell for prenatal diagnosis is propelled by the need to accurately identify microdeletions and non-X-linked monogenic diseases in the fetus. We look forward to working closely with Yourgene as our downstream NGS expert in this collaboration.”
“We are excited to be working with Abnova which has developed end-to-end solutions for the upstream CTC and CFC enrichment, identification, and isolation,” said Dr. Bill Chang, President of Yourgene. “In the biotech community, collaboration is essential to spearhead the products into the market which rewards the first movers. Many companies have great technologies and innovations but the final commercialization is often hampered by critical factors which can be solved more quickly by open integration and collaboration. Moreover, we are also seeing the focus of NGS shifting from the academic research to clinical applications. This is an area of strength for Yourgene.”
They created a product that infringes several patents and gloss over it as "a bump in the road". The "freedom to operate" was not worth the paper it was written on, they extend a massive line of credit to genoma that they won't get back. The seed investors bailed and we were told all was well and it wasn't a problem. So with all due respect the company have let their PIs down. Fact. It's an omnishambles.
Trying to arrange meeting with BOD in the first instance. If interested contact vanvagabond at eye cloud dot com. We need answers.
As per query to the company - it all depends on what the deal entails - for example if we bolt on reagents , machines etc then we get more but if they already deal direct with TF then we are not involved in Reagents etc We have a vast array of deals of different descriptions - however the thing to remember is simply that each deal embeds us more and more into the TF infrastructure- WE are there chosen in road into the NIPT arena. TF are very happy with their ingress into the global NIPT market thus far.
The RNS will not be a 7:00 or an after hours RNS - it will be, by necessity, intraday. The judge will communicate the decision at sometime through the day - an RNS will be massively commercial sensitive and won't wait until the end of the day - eg the American market could be away awake whilst ours is closed. We will know via share price movement and social media / the press prior to an RNS being drafted with the applicable wording, signed off then issued. Unless they have a generic version of a "win,lose or draw" version of an RNS prepared and ready to be issued immediately and padded out in a subsequent RNS.
A win will rocket the price - even with an appeal. Illumina have not won a single court case nor appeal. We had a freedom to operate ackowldegement which is given after looking at the applicable patents in the arena. If they thought infringed they simply would not have proceeded - they would have licenced it from them and used illuminas platforms. They didn't as it's a long game in a platform war. To me an appeal is meaningless.
I'm counting the days until the snake turns.... I can't believe people are interacting with him.... Short memories.......
It's an already profitable company - it takes years for AIM companies to make a dime! If they ever do at all... As soon as this is seen by the market then I expect an initial spike - this will fly on small volume - and they need to communicate figures soon..... AR et al are not stupid and know what they are doing - AR is a money making machine - ride his coat tails......